The Future of Systemic Lupus Erythematosus Treatment: The Promise of Selective Immunotherapies, Anifrolumab and Belimumab, Compared to Blanket Immunosuppressives
August 2024
TLDR Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.
The review discusses the potential of selective immunotherapies, specifically anifrolumab and belimumab, in treating systemic lupus erythematosus (SLE) compared to traditional blanket immunosuppressives. Anifrolumab targets type I interferons, while belimumab neutralizes BLyS, both aiming to reduce autoantibody production, the root cause of SLE. These targeted therapies are shown to be more effective in managing lupus by focusing on specific immune system components rather than broadly suppressing symptoms. The paper also reviews clinical trial results for these therapies, highlighting their promise in improving SLE treatment outcomes.
